Adams Capital Management
All Portfolio Companies Information Technology: Networking Infrastructure Other Featured Exits  

Current Portfolio

Information Technology:

Networking Infrastructure


Featured Exits

Precision Therapeutics

Precision Therapeutics

Initial Investment:



Pittsburgh, Pennsylvania

ACM Deal Team:

Joel Adams
William Frezza


Precision Therapeutics (PTI) is committed to improving outcomes of cancer patients. Known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, PTI develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer. PTI's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician with the goal of optimizing patient outcomes.

Recent Precision Therapeutics News

June 26, 2014 Two Pivotal Manuscripts on ChemoFx Accepted for Publication
February 24, 2014 Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology
prevnextBack to Portfolio Page